Skip to content
Reflections of yellow marbles on metal holders
Reflections of yellow marbles on metal holders

Life Sciences

Our global Life Sciences practice comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, veterinary, medtech, diagnostics and healthcare sectors.

The practice operates on a cross-border basis and covers the full spectrum of legal support. We advise on mergers and acquisitions, commercial transactions (including licensing and collaborations), IP (both contentious and non-contentious), capital markets and finance, regulatory and dispute resolution. Our international network ensures that we have a ready resource of expertise in a number of jurisdictions, including those in emerging markets, and that we are well positioned to advise on cross-border work.

We have won a reputation for providing far-sighted advice to some of the world’s leading life science companies.

News and insights

Long exposure shot of traffic lights moving over a road.

Publications: 10 January 2023

The EU and UK adopt further sanctions against Russia

At the close of 2022, and with the war in Ukraine entering its tenth month, the EU and the UK adopted further sanctions packages against Russia. The latest sanctions packages include further asset…

Read more
Heap of medical pills in white, blue and other colors. Pills in plastic package. Concept of healthcare and medicine.

Blog Post: 04 January 2023

Why AI drug discovery deals are different from traditional pharma collaborations

Pharma companies have been working with artificial intelligence (AI) for a decade or more. As the cost and time of bringing a new drug to market continues to rise, pharma companies are increasingly…

Read more

Publications: 20 December 2022

Why AI drug discovery deals are different from traditional pharma collaborations

Pharma companies have long collaborated with other organisations to bring new drugs to market. But what happens when their partner is an artificial intelligence (AI) company rather than another pharma…

Read more
Medical vials in production

Publications: 09 December 2022

What corporate data tells us about future M&A activity

We track a range of metrics to assess the likelihood of future deal activity across sectors. This analysis points to hotspots of M&A in tech, consumer, life sciences and possibly mining in the year to…

Read more

Recognition

Related links

Life Sciences Hub

We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector.

Read more

CRISPR microsite

The characterisation and optimisation of the CRISPR (also known as CRISPR-Cas) system for gene editing and other applications, is undoubtedly one of the most powerful and ground breaking advances in the history of biotechnology.

Go to microsite

Growth Capital microsite

Allen & Overy is an engaged and active player in the growth company ecosystem.

Go to microsite

UPC microsite

Ready for take-off

Go to microsite

Download our sector brochure

Life sciences A&O red molecules

Our Life Sciences and Healthcare sector focus 2022

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.

Related content

Global trends in merger control enforcement

Record levels in the first half of 2018 and considerable contraction in the second.